Effect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium

Plain-language guide to NCT06930391: not phased randomized trial of Oxytocin and Carbetocin, 40 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06930391
Phase: not phased
Status: recruiting participants
Start: 2025-09-15
Completion (planned or actual): 2026-06
Participants: 40 (estimated)
Design: randomized, open label (everyone knows who gets what), treatment
Conditions studied: Postpartum Hemorrhage (Primary)
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered not phased trial tested Oxytocin and Carbetocin.

Carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for PPH prophylaxis at cesarean delivery.

It had six arms (groups): Calcium 1.25nM with NO oxytocin pre-exposure (active comparator), Calcium 2.5nM with NO oxytocin pre-exposure (active comparator), Calcium 5.0nM with NO oxytocin pre-exposure (active comparator), Calcium 1.25nM with oxytocin pre-exposure (active comparator) and Calcium 2.5nM with oxytocin pre-exposure (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 40 planned participants were the target.

It was open to women only aged from 18 years up to 40 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Non-laboring women with gestational age between 37 to 41 weeks. Not exposed to exogenous oxytocin, scheduled for a primary or first repeat cesarean delivery under neuraxial anesthesia.

The full record lists 2 inclusion and 6 exclusion criteria; among the exclusions: patients requiring general anesthesia; more than 1 previous cesarean delivery; history of uterine atony.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Oxytocin study: the participants and staff both knew the treatment.

It started in 2025-09-15 with completion listed for 2026-06.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Motility index (time frame: 4 hours).

It also tracked 3 secondary outcomes, for example Amplitude of contraction, Frequency of contraction and Integrated area under response curve (AUC).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Oxytocin and Carbetocin in 40 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page and the Carbetocin compound page, all human trials.

Our Notes on the Compounds

Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.

Carbetocin: A long-acting oxytocin analog used outside the US to prevent bleeding after childbirth; also studied intranasally in Prader-Willi syndrome.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.